$25.62
+3.98 (+18.39%)
Open$24.84
Previous Close$21.64
Day High$27.32
Day Low$22.30
52W High$35.00
52W Low$10.06
Volume—
Avg Volume270.6K
Market Cap278.91M
P/E Ratio—
EPS$-35.44
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-69.0% upside
Current
$25.62
$25.62
Target
$7.94
$7.94
$5.53
$7.94 avg
$9.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.06M | 7.75M | 49.01M |
| Net Income | -352,342,408 | -485,766,187 | -2,802,997 |
| Profit Margin | -6,960.8% | -6,612.7% | -5.7% |
| EBITDA | -60,496,237 | -88,038,335 | -4,562,575 |
| Free Cash Flow | — | — | -4,055,082 |
| Rev Growth | -34.7% | -34.7% | +7.4% |
| Debt/Equity | — | — | 0.82 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |